AAD 2026: RelabotulinumtoxinA Shows Consistent Efficacy Across Age Groups

A post hoc analysis presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated the impact of age on outcomes with relabotulinumtoxinA in patients with moderate-to-severe glabellar lines (GLs) and lateral canthal lines (LCLs). The analysis pooled data from three Phase 3 randomized, double-blind, placebo-controlled trials.

A total of 1012 subjects were included, with patients stratified into age groups of 20–35 years, >35–50 years, and >50–60 years. Across both GL and LCL cohorts, relabotulinumtoxinA achieved high responder rates, defined as at least a 1-grade improvement on investigator- and subject-assessed scales, through 6 months of follow-up.

Responder rates were consistently higher with relabotulinumtoxinA compared with placebo across all age groups. Data presented in responder curves showed slightly greater treatment responses among younger patients, particularly in LCL assessments, though meaningful improvements were observed in all cohorts. Treatment effects peaked early and gradually declined over time but remained above placebo at 6 months.

Patient-reported outcomes mirrored these findings. Satisfaction with both appearance and treatment remained high across age groups, with the highest scores observed in younger participants. Psychological function scores also trended higher in treated patients compared with placebo, particularly in younger cohorts.

Safety findings were consistent across age groups, with most treatment-related adverse events described as mild or moderate. No new safety signals were identified.

“In all 3 age groups, subjects treated with relabotulinumtoxinA achieved high rates of ≥1-grade improvement…along with high rates of satisfaction with treatment and appearance through 6 months,” the authors concluded.